Mast cell-associated mediators are generally classified into two groups: the preformed mediators, which are stored in the cells' cytoplasmic granules and are released upon exocytosis, and the newly synthesized mediators, which are not stored but are produced and secreted only after appropriate stimulation of the cell. We now report that tumor necrosis factor a (TNF-cr)/cachectin represents a new type of mast cell-associated mediator, in that IgE-dependent mast cell activation results in the rapid release ofpreformed stores of the cytokine followed by the synthesis and sustained release of large quantities of newly formed TNF-a. We also demonstrate that challenge with specific antigen induces higher levels ofTNF-a mRNA at skin sites sensitized with IgE in normal mice or mast cell-reconstituted genetically mast cell-deficient WBB6Fi-W/ W°mice than at identically treated sites in WBB6FvW/ W°mice that are devoid of mast cells . These findings identify mast cells as a biologically significant source of TNF-a/cachectin during IgE-dependent responses and define a mechanism whereby stimulation of mast cells via the FCERI can account for both the rapid and sustained release of this cytokine .
T he biologically active mediators elaborated by mast cells are traditionally assigned to two groups (1, 2) . One class of mediators, which includes histamine, serotonin, heparin, and other proteoglycans, and certain proteases, are stored in the cells' cytoplasmic granules. While extracellular release of these products is an energy-dependent process, expression of the bioactivities requires only exocytosis of cytoplasmic granules containing the preformed mediators . By contrast, another class of mediators, which includes products of the cyclooxygenase or lipoxygenase pathways ofarachidonic acid metabolism and platelet activating factor, are not stored by mast cells, but are synthesized and released upon activation of the cells. However, several recent findings indicate that it may not be appropriate to classify all mast cell-associated mediators as either preformed or newly synthesized. It is now clear that in vitro derived mouse mast cells stimulated via the FCERI or by other mechanisms can express increased levels ofmRNA for a wide range o£multifunctional cytokines and, in some instances, release the products (3) (4) (5) (6) . In the case of one of these cytokines, TNF-a/cachectin, both in vitro derived and freshly purified mouse mast cells also constitutively store significant amounts of the bioactivity (6) . The presence of preformed stores of TNF-a in mast cells is of interest, in that other cell types that produce this cytokine, such as macrophages (7) (8) (9) , T cells (10) , and B cells (11) , contain little or no detectable TNF-cr unless they are appropriately stimulated. We recently showed that stimulation of mouse mast cells via the FCERI resulted in both the release of TNF-a bioactivity and also increased levels ofTNF-a mRNA (6) . However, the extent to which the TNF-a bioactivity released by activated mast cells reflected the secretion of preformed as opposed to newly synthesized cytokine was not determined .
In the present study, we demonstrate that the TNFc t/cachectin released by mouse mast cells upon IgE-dependent stimulation is derived from two distinct pools, a preformed pool, which accounts for most of the product released during the first 10 min after stimulation, and a newly synthesized pool, which accounts for the later, sustained release of the cytokine. These findings indicate that TNF-a/cachectin represents a new type of mast cell-associated mediator, which expresses bioactivity through the effects of both preformed and newly synthesized product .
Materials and Methods
Cells. The derivation of the 11,3-independent cloned mast cell line CLMC/C57 .1 has been reported (12) . Primarycultures of IL3-dependent, bone marrow-derived cultured mast cells (BMCMC)' and purified peritoneal mast cells (PMC) were prepared from retired breeder BALB/c mice (6) . BMCMC (>95% mast cells by staining with neutral red) were used 4-5 wk after the initiation of culture (6) . Purified PMC contained >98% mast cells according to neutral red staining (6) . The L929 cell line was obtained and maintained as reported (6, 12) . For FcERI-dependent activation, mast cells were sensitized with a monoclonal (mc) IgE antidinitrophenol (DNP) antibody (13) for 3 h (6). The CLMC/C57 .1 cells and BMCMC were then stimulated with DNP_~o_4o HSA (50 ng/ml; Sigma Chemical Co., St . Louis, MO) (5, 6), whereas PMC were challenged with a rat me anti-mouse IgE (150 ng/ml final concentration) (6) . In experiments measuring the release of preformed, as opposed to newly synthesized TNF-a, the transcription inhibitor actinomycin D (act D, 10 t~g/ml; Sigma Chemical Co .) was added to the cultures 5-10 min before activation of the cells with antigen or anti-IgE .
Measurement of TNFa Secretion. TNF-a bioactivity in mast cell supernatants was detected using an MTT 18-h cytotoxicity assay with L929 target cells (6) . The specificity of the cytotoxic activity was determined by neutralization with a monospecific rabbit anti-TNF-a antisera (6) , and recombinant murine TNF-a (Genzyme, Boston, MA) standards were included in each assay. Statistical analysis of the data was performed using a two-tailed Students t test .
Serotonin Release Assay. To evaluate the release of a classical preformed mediator, we monitored the kinetics of release of the cytoplasmic granule-associated mediator serotonin Isolation of RNA. RNA was obtained from the cultured cells as described (5, 6) and from mouse skin specimens after homogenization in guanidinium isothiocyanate solution (5, 6) using a tissue homogenizer (Polytron, Kinematica GmbH Littau, Switzerland) . The homogenates were cleared by centrifugation for 30 min at -16,000g, the cellular RNA was isolated (5, 6) , and the mRNA was purified by oligo d(T) cellulose chromatography (6) .
Northern Blotting of RNA. Briefly, the RNA was size fractionated on formaldehyde-agarose gels and transferred to nylon membranes (Zeta-bind; Cuno Laboratories, Meriden, CT). The blots were hybridized with "P-labeled specific cDNA probes, washed at high stringency, and photographed (6) . In some experiments, the signals on the autoradiographs were quantitated by laser densitometry, and the results corrected for variation in RNA loading, as determined by reference to control (actin) cDNA probes.
Molecular Probes for Detection of Cytokine mRNA . The 1-kb TNF-ci cDNA probe (15) , an EcoRI fragment from a plasmid generously provided by Dr. Michael Palladino (Genentech, Inc., South 1 Abbreviations used in this paper: act D, actinomycin D; BMCMC, bone marrow-derived cultured mast cells; 5-HT, 5-hydroxytryptamine; LPR, late phase reaction; mc, monoclonal; PCA, passivecutaneous anaphylaxis; PMC, peritoneal mast cells.
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Two Distinct Pools of Tumor Necrosis Factor a/Cachectin San Francisco, CA), was body labeled with [12 p]dCTP using the random hexamer priming method. A synthetic oligonucleotide probe (sequence: 5'-GTCCCCCTTCTCCAGCTGGAAGACT CCTCC-3') specific for exon 4 of murine TNF-a (16) was generously provided by Dr. Glen Andrews (Pfizer Pharmaceuticals, Groton, CT) and was 3' labeled with [32 p]ATP using the terminal deoxynucleotidyl transferree reaction . Both probes were used as noted (6) . Determination of TNF-ci mRNA Half-Life. Briefly, 60-90 min after immunologic activation of the mast cells, act D (10 wg/ml) was added to the cell cultures to block nascent transcription, and at varying intervals thereafter, the residual cellular mRNA was extracted from the cells and analyzed by Northern blotting. The amount of specific mRNA was quantified by laser densitometry (above) and the biologic half-life (t3/2) determined from the graphed results.
Induction of Passive Cutaneous Anaphylaxis (PCA) Responses. Briefly, we injected x+48 ng of me IgE anti-DNP antibody in 20 Pl of Hepes-buffered HBSS (Hepes-HBSS) intradermally into the ears. After 24 h, the mice were challenged intravenously with 100 ug of DNP3o-ao-HSA (Sigma Chemical Co.) in 200 ul of Hepes-HBSS containing 0.5% Evan's blue dye. The presence of PCA reactivity was confirmed by measuring the ear swelling (A ear thickness) and/or by assessing the extravasation of Evan's blue dye (17) . At 45 min after antigen challenge, ear biopsies were processed for RNA extraction and Northern analysis as noted above.
Local Cutaneous Mast Cell Reconstitution of W/W°Mice. The chronic application of PMA to the skin of genetically mast cell-deficient WBB6F,-W/W°mice induces the development of large numbers of phenotypically normal dermal mast cells that are competent to orchestrate PCA reactions (17) . This effect is localized to the PMA-treated site ; mast cells do not develop at contralateral sites treated with vehicle (acetone) alone (17) . The mast cells that develop at PMA-treated sites persist for at least 8 wk after the PMA treatments are stopped and the local inflammatory responses have waned (our unpublished results) . For the experiments reported here, we induced mast cell development in the ear skin of W/W°mice by chronic application of PMA (5 wg/site in 5 A1 of acetone, three times per week for 6 wk); the contralateral ears were treated on the same schedule with acetone alone (17) . The animals were then left untreated for an additional 6-8 wk, to permit the local inflammatory reactions to subside.
Results and Discussion
Kinetics of Induction of TNF-alCachectin mRNA in Mast Cells Stimulated via the FCAL We first determined the kinetics of TNF-Q mRNA induction in CLMC/C57 .1 mast cells stimulated via the FcERI (Fig. ') .TNF-cat mRNA increased to very high levels by 30-60 min after challenge, then gradually waned by 4-6 h after stimulation. We showed that the signals in these blots indeed represented TNF-ci mRNA by probing similar blots with an oligonucleotide probe specific for exon 4 of TNF-cx (Fig. 1) . Primary populations of IL3-dependent BMCMC stimulated with IgE and specific antigen exhibited kinetics of TNF-ca mRNA induction that were the same as those observed with CLMC/C57.1 mast cells (data not shown) . The t1i2 of TNF-ca mRNA in either CLMC/ C57.1 cells or BMCMC was -35 min.
Kinetics of Release of Preformed or Newly Synthesized TNFalCachectin by Mast Cells. To assess the contribution of preformed as opposed to newly synthesized TNF-a/cachectin to the cytokine bioactivity released upon IgE-dependent mast cell stimulation, we activated the cells either in the presence (+) or absence (-) of act D (Fig . 2) . Identically treated mast cells that first had been permitted to incorporate [3H]5-HT were also tested, to determine whether act D treatment influenced release of the cytoplasmic granule-associated preformed mediator 5-HT (Fig. 2) . In C1 .MC/C57 .1 mast cells tested in the absence of act D (Fig. 2 a) , release of
[ 3H]5-HT reached maximal levels within 10 min of antigen challenge, whereas release of TNF-a bioactivity did not achieve maximal levels until 60 min after challenge . In the presence of act D (Fig. 2 b) , the C1 .MC/C57 .1 mast cells released substantially less TNF-ci bioactivity, which reached maximal levels by 10 min and actually declined thereafter (Fig. 2 b) . Note that data for TNF-a release in Fig . 2 , a and b are shown on a log scale ; maximal levels of release of preformed TNF-a (Fig. 2 b) represented only -10% of the maximal levels of cytokine released by cells stimulated in the absence of act D (Fig. 2 a) . Similar results were obtained with BMCMC and purified PMC (Fig . 2 c) .
Taken together, these experiments show that in cloned mast cells, primary cultures of immature IL-3-dependent mast cells, and purified mature PMC, FcERI-dependent activation results in the rapid release of preformed stores of TNFa/cachectin followed by the sustained release of substantially greater amounts o£ newly formed cytokine. In contrast to its dramatic effect on TNF-ci release, incubation with act D had no discernable effect (p > 0.05 at all time intervals) on IgE-dependent release of [ 3 H]5-HT from any of the mast cell populations (Fig. 2, a-c) . The latter results indicated that the effect of act D on TNF-a release did not reflect an impairment of mast cell exocytosis per se, but instead was due to its ability to block the synthesis of TNF-a in response to IgE-dependent stimulation of the cells.
Mast Cells Represent a Major Source of TNF-ci mRNA In Viva To determine if mast cells represented a significant source of TNF-ci during IgE-dependent immunological responses in vivo, we searched for TNF-a mRNA in the skin of normal (WBB6Ft-+/+) mice, genetically mast celldeficient WBB6Ft-W/W°mice, and mast cell-reconstituted WI WI mice after sensitization of the cutaneous sites with me IgE anti-DNP and intravenous challenge of the animals 24 h later with DNP-HSA (Fig. 3) . As reported previously (17, 18), significant tissue swelling occurred in association with 30-min PCA reactions in +/+ mice but not at identi- cally treated sites in genetically mast cell-deficient W/ W°m ice ( Fig. 3 a, left pane4 . When laser densitometry was used to determine the ratios of TNF-a and actin mRNA (relative TNF-a mRNA content) in the ears, substantially more TNF-a mRNA was present in the +/+ than in the mast cell-deficient W/W" mouse ears (Fig. 3 a, right pane . We then repeated the experiment, but in this case we injected me IgE anti-DNP into the mast cell-deficient and contralateral mast cell-reconstituted ears of W/W°mice, and then challenged the animals with DNP-HSA 24 h later. In accord with our previous study (17), extravasation of Evan's blue dye indicated that PCA reactions developed in the mast 10 6 Two Distinct Pools of Tumor Necrosis Factor u/Cachectin cell-reconstituted but not in the contralateral mast celldeficient ears, and substantially more TNF-a mRNA was present in the mast cell-reconstituted than in the mast cell-deficient ears (Fig. 3 b) . The present study shows that mast cell production of TNFa/cachectin after IgE-dependent stimulation differs significantly in both mechanism and kinetics from the IgE-dependent release ofsuch classical cytoplasmic granule-associated mediators as 5-HT Several lines of evidence, including the experiments reported here, indicate that the release of 5-HT and other preformed mediators reflects primarily the secretion of product already stored in the cells' granules at the time of cell activation (reviewed in references 1 and 2). By contrast, IgE-dependent stimulation of the mast cell induces both the rapid release of preformed TNF-a, which is secreted with a kinetics similar to that of 5-HT, as well as the synthesis and secretion of large amounts of newly formed TNF-a .
These findings have several important implications. They identify TNF-a/cachectin as the first of what arguably represents a new class of mast cell-associated mediators : those that are released with a prolonged kinetics reflecting the contributions of both preformed and newly synthesized pools of product . These findings also identify a mechanism by which the effects of mast cell-derived TNF-a can be sustained for long periods of time during biological responses . Mast cells have been proposed as a major source of the mediators that regulate late phase reactions (LPRs), which in turn are regarded as a major cause of the tissue injury and morbidity associated with asthma and other chronic, IgE-dependent disorders (reviewed in references 1 and 19) . In addition to a myriad of other biological actions (7, 8) , TNF-a/cachectin can promote leukocyte recruitment through effects on both vascular endothelial cells and leukocytes (reviewed in references 2, 20, and 21) . The sustained release of TNF-ca by mast cells stimulated via the FcERl thus represents a potential mechanism by which mast cells can orchestrate leukocyte recruitment during LPRs and other biological responses. In support of this hypothesis, we showed that leukocyte recruitment during IgEdependent cutaneous LPRs in the mouse was virtually entirely mast cell dependent, and that leukocyte infiltration into these reactions was substantially reduced by injection of these sites with antibodies to mouse recombinant TNF-a (22) .
Our findings may also have implications for the therapy of diseases thought to involve mast cells. Conventional therapeutic approaches to mast cell-associated disorders include attempts to interfere with mast cell activation, with agents such as sodium cromoglycate, or to antagonize the end organ effects of mast cell mediators, with agents such as antihistamines or antagonists of lipid mediators (1, 2) . The finding that substantial amounts of the TNF-ca produced by mouse mast cells reflects product synthesized after the initial stimulation of the cell, taken together with evidence that human skin (23) and lung (24) mast cells represent potential sources of TNF-a, suggests that agents that can interfere with the synthesis of TNF-a or other cytokines by mast cells may favorably affect the course of certain mast cell-associated disorders (25) .
